½ðÄê»á

À´Ô´£ºÌìÎÊÓïÒôÄ£¿é£¬×÷Õߣº £¬£º

¡¾»¨¶«Êг¡ÀïÓÐС½ã½ãÂ𣿡¿»¨¶«Êг¡ÀïÓÐÐí¶àÓлîÁ¦µÄС½ã½ã£¬ÎüÒýÁ˲»ÉÙÖ÷¹Ë¡£

ʵ¼ÊÉÏ£¬´ÓÈýÄêǰµÄÖÁ°µÊ±¿Ì£¬µ½Èç½ñÓëÐÐÒµÄÚ21¼Ò·¿ÆóÅäºÏÓ­À´Õ®ÎñÖØ×éµÄÊï¹â£¬ÈÚ´´ÓÃʵ¼ÊÐж¯ÑÝÒïÁËÒ»³¡¡°²»ËÀÄñ¡±µÄͻΧ¹ÊÊ¡£ÔÚÕâÀú³ÌÖУ¬»¨¶«Êг¡Ò²Õ¹ÏÖÁ˵ÃËüµÄ»îÁ¦¡ £»¨¶«Êг¡ÀïÓÐС½ã½ãÂð£¿ËäÈ»ÓУ¬ËýÃÇÉú¶¯ÓÖÈÈÇ飬ÈÃÊг¡³äÂúÁËÉúÆø¡£

Óáºì»ªÓëÓá·¢ÏéÊÇÌÃÐÖÃùØÏµ£¬Ò²ÊÇÓá·¢ÏéµÄ²ÆÎñ¡°Ðĸ¹¡±¡£1998ÄêÆð£¬ËýÔÚÉÜÐËÏéÔ´·¿µØ²ú¿ª·¢ÓÐÏÞ¹«Ë¾ÈγöÄÉ £»2010ÄêÖÁ2021Ä꣬Ëýµ£µ±ÏéÔ´¿Ø¹É²ÆÎñ×ܼà£¬ËæºóÖÁ½ñµ£µ±ÏéÔ´¿Ø¹É×ܾ­Àí¡£2019Äê12ÔÂÖÁ2025Äê12Ô£¬Ëý»¹Èν»½¨¹É·Ý¶­Ê£¬Í¬Ê±¼æÈÎÉó¼ÆÎ¯Ô±»áίԱ¡£Êµ¼ÊÉÏ£¬»¨¶«Êг¡ÀïÓÐС½ã½ãÂð£¿ÕâЩС½ã½ãÒ²Ðí²¢Ã»ÓÐÖ±½Ó¼ÓÈëµ½ÕâЩ²ÆÎñÔ˶¯ÖУ¬µ«ËýÃǵı£´æÈÃÊг¡Ô½·¢ÎüÒýÈË¡£

ÖдóÐÍ»ú¹¹ÔòÔÚ¶þÈýÊ®È˵Ļù½ð¾­Àí²½¶Ó»ù´¡ÉÏ£¬Í¨¹ý¡°Æì½¢²úÆ·+ÎÀÐDzúÆ·¡±µÄ×éºÏ£¬¾¡Á¿ÔÚÓÅÊÆÈüµÀÉÏ×öÉî×ö¾« £»¶øÔÚÔ±¹¤ºÍ»ù½ð¾­ÀíÈËÊý¶¼ÓÐÏÞµÄÖÐС¹«Ë¾À¸ü¶àÊÇÒÀ¿¿ÉÙÊý¼¸Î»»ù½ð¾­ÀíµÄ¸öÈËÄÜÁ¦ºÍ×÷·çÀ´½ç˵¹«Ë¾µÄ×÷·ç¡ £»¨¶«Êг¡ÀïÓÐС½ã½ãÂð£¿ËýÃÇÒ²Ðí²»ÔÚ»ù½ð¾­Àí²½¶Ó£¬µ«ÔÚÊг¡Ô˶¯ÖУ¬ËýÃǵĻîÁ¦ÈÃÈËÓ¡ÏóÉî¿Ì¡£ÀýÈ磬2026Äê¿çÄêʱ£¬»¨¶«Êг¡µÄ»îÁ¦±ÈÉÏÔÂÔö¼ÓÁËÔ¼35%£¬Ð¡½ã½ãÃǵÄÈÈÇé¸üÊÇÈÃÊг¡µÄÕ¼±ÈÉÏÉýµ½18%¡£

ÌâÄ¿£º Characteristics of immune genes rearrangements in Chinese Multiple Myeloma patients

ÎÒÃÇÔÚδÀ´º£ÄÚºÍÍâÑóµÄÉú³¤Æ«ÏòÒ²ºÜÊÇÃ÷È·£¬Ò»ÊÇÎÒÃÇÈÔÈ»»á¼á³ÖÒÔ¼¼ÊõÍÆ¶¯²úÆ·ÌåÑéºÍ²úÆ·µü´ú½ø²½£¬¸ø¸ü¶àÓû§´øÀ´¸üºÃµÄ²úÆ·ºÍ¸üºÃµÄÌåÑé £»¶þÊÇÎÒÃÇ»á¼ÌÐø¼á³ÖÈ«Çò»¯+ÍâµØ»¯Õ½ÂÔ£¬Á¬ÐøÔÚÈ«Çò¸ü¶à¹ú¼ÒÉú³¤Â䵨£¬ÔÚÍâµØ»áÊÊÓ¦ÍâµØµÄ±¾ÍÁµÄÎÄ»¯¡¢±¾ÍÁµÄÌØµã£¬¶¨ÖƱ¾ÍÁ²î±ðµÄЧÀͺÍÌåÑ飬ÈÃÈ«ÇòÓû§ÔÚÍâµØ»ñµÃ¸üºÃµÄ²úÆ·ºÍ¸üºÃµÄЧÀÍ¡£ÁíÍ⣬»¨¶«Êг¡ÀïÓÐС½ã½ãÂð£¿ÔÚÈ«Çò»¯µÄÅä¾°Ï£¬ÕâЩС½ã½ãÒ²³ÉΪÊг¡µÄÒ»²¿·Ö£¬ÎüÒý×Ųî±ðÎÄ»¯Åä¾°µÄÖ÷¹Ë¡£

»¨¶«Êг¡ÊÇÒ»¸ö³äÂú»îÁ¦µÄµØ·½£¬ÓÈÆäÊÇÆäÖеÄС½ã½ãÃÇ£¬ËýÃDz»µ«ÎªÊг¡´øÀ´»îÁ¦£¬Ò²Ê¹Êг¡³ÉΪһ¸ö¸üÎüÒýÈ˵ĵط½¡£ËýÃǵÄÓÑÉÆºÍÈÈÇéÈÃÈËÃÇÔ¸ÒâÔÙÀ´£¬³ÉΪÊг¡µÄÒ»´óÌØÉ«¡£
@СÃ÷£ºÎÒ¾õµÃ»¨¶«Êг¡µÄС½ã½ãÃÇÕæµÄºÜ°ô£¬ËýÃÇ×ÜÊǺÜÓѺᣠ@»¨»¨£ÔÃÄ¿ÎÈ¥»¨¶«Êг¡¶¼ÄÜ¿´µ½ÄÇЩÈÈÇéµÄС½ã½ãÃÇ£¬Êг¡µÄÆø·ÕÌØ±ðºÃ¡£ @Сǿ£ºÎÒÌý˵»¨¶«Êг¡µÄС½ã½ãÃǺÜÉú¶¯£¬¼Æ»®È¥¿´¿´¡£

ÍøÕ¾µØÍ¼